Merck & Company (MRK) 57.65 $MRK
Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets
BusinessWire - Wed Aug 03, 12:23PM CDT
Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.
MRK: 57.65 (-0.68), NVS: 82.40 (-0.56)
Merck Set to Possibly Rebound After Yesterday's Selloff of 1.37%
Comtex SmarTrend(R) - Wed Aug 03, 12:06PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.18 to a high of $58.30. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.25 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.65 (-0.68)
SmarTrend Watching for Potential Rebound in Shares of Merck After 1.37% Loss
Comtex SmarTrend(R) - Wed Aug 03, 12:04PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.18 to a high of $58.30. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.25 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.65 (-0.68)
Pharma ETFs Soaring on Solid Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 11:22AM CDT
Pharma ETFs are in focus in the days ahead on impressive Q2 results.
IHE: 156.52 (+0.77), BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), PPH: 61.96 (+0.06), PJP: 68.56 (+0.47), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), XPH: 46.68 (+0.54), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Merck's KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
BusinessWire - Tue Aug 02, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU member states.
MRK: 57.65 (-0.68)
Biogen (BIIB) Stock Surges 8% on Takeover Rumors
Afrasiab Mian - Zacks Investment Research - Tue Aug 02, 3:10PM CDT
Biogen (BIIB) stock jumped 8% on late-afternoon trading on Tuesday on rumors that the company could be bought out by either Allergan (AGN) or Merck (MRK), both large-cap pharmaceutical companies.
AGN: 252.53 (+1.78), BIIB: 321.34 (-8.77), MRK: 57.65 (-0.68), IONS: 37.73 (-0.01)
Global Pain Management Therapeutics Market - Patent Expiries of Blockbuster Drugs to Intensify Challenges for Branded Drugs, States TMR; Industry Analysis, Size, Share, Growth, Trends, Forecast up to 2023
PR Newswire Europe - Tue Aug 02, 8:31AM CDT
ALBANY, New York, August 2, 2016 /PRNewswire/ --
PFE: 35.29 (-1.10), MRK: 57.65 (-0.68)
Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 57.65 (-0.68), EXPE: 112.56 (-0.99), ABBV: 66.57 (-0.21), XRX: 9.94 (+0.13)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
Rheumatoid Arthritis (RA) Drugs Markets 2016-2026
PR Newswire Europe - Mon Aug 01, 8:01AM CDT
LONDON, August 1, 2016 /PRNewswire/ --
MRK: 57.65 (-0.68)
Nanoco and Merck Sign Agreement to Market Cadmium-free Quantum Dots
BusinessWire - Mon Aug 01, 8:00AM CDT
Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots (CFQD(R) quantum dots) and other nanomaterials, today announced it has signed a worldwide material supply and licensing agreement with Merck, a leading science and technology company. The license allows Merck to immediately start marketing Nanoco's CFQD quantum dots and to ultimately establish its own production facility to meet growing market demand for this innovative, heavy metal-free material.
MRK: 57.65 (-0.68), NANO: 19.70 (-0.23)
Leading Chief Privacy Officer Hilary Wandall Joins TRUSTe as Demand Escalates for Global Privacy and Data Protection Solutions
PR Newswire - Mon Aug 01, 8:00AM CDT
TRUSTe, the leading Data Privacy Management company, announced today that Hilary Wandall, Associate Vice President, Compliance and Chief Privacy Officer at the global pharmaceutical company, Merck & Co. Inc., has joined TRUSTe as General Counsel and Chief Data Governance Officer. In this role, Hilary will use her extensive global privacy knowledge and operational experience to help TRUSTe further expand their market leading privacy technology and service offerings to support rising global compliance requirements and privacy risk management. She will be a member of the TRUSTe Executive Team and also direct strategic legal, regulatory and privacy related initiatives to help TRUSTe scale its internal business operations.
MRK: 57.65 (-0.68)
Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound
PR Newswire Europe - Mon Aug 01, 7:01AM CDT
- Includes scale-up and GMP manufacturing of drugs in late-stage development
MRK: 57.65 (-0.68)
Mylan Launches Generic Propecia® Tablets
PR Newswire - Mon Aug 01, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Finasteride Tablets USP, 1 mg, a generic version of Merck's Propecia®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
MRK: 57.65 (-0.68), MYL: 48.41 (+1.88)
Business Highlights
By The Associated Press - AP - Fri Jul 29, 4:01PM CDT
___
FDX: 160.61 (+1.43), AMZN: 754.64 (-5.94), BUD: 123.65 (-0.98), MRK: 57.65 (-0.68), SNE: 32.35 (-0.15), BP: 33.01 (-0.44), CVX: 100.61 (+1.02), UPS: 108.29 (+0.83)
Merck (MRK) Breaks Through Resistance at $58.64
Comtex SmarTrend(R) - Fri Jul 29, 9:19AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $58.38 today and have reached the first resistance level of $58.64. Investors may be interested in a cross of the next upside pivot targets of $58.86 and $59.34.
MRK: 57.65 (-0.68)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 123.90 (-0.95), MRK: 57.65 (-0.68), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets
BusinessWire - Wed Aug 03, 12:23PM CDT
Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.
MRK: 57.65 (-0.68), NVS: 82.40 (-0.56)
Merck Set to Possibly Rebound After Yesterday's Selloff of 1.37%
Comtex SmarTrend(R) - Wed Aug 03, 12:06PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.18 to a high of $58.30. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.25 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.65 (-0.68)
SmarTrend Watching for Potential Rebound in Shares of Merck After 1.37% Loss
Comtex SmarTrend(R) - Wed Aug 03, 12:04PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.18 to a high of $58.30. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.25 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.65 (-0.68)
Pharma ETFs Soaring on Solid Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 11:22AM CDT
Pharma ETFs are in focus in the days ahead on impressive Q2 results.
IHE: 156.52 (+0.77), BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), PPH: 61.96 (+0.06), PJP: 68.56 (+0.47), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), XPH: 46.68 (+0.54), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Merck's KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
BusinessWire - Tue Aug 02, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received approved therapy for these mutations prior to receiving KEYTRUDA. The EC approval allows marketing of KEYTRUDA in all 28 EU member states.
MRK: 57.65 (-0.68)
Biogen (BIIB) Stock Surges 8% on Takeover Rumors
Afrasiab Mian - Zacks Investment Research - Tue Aug 02, 3:10PM CDT
Biogen (BIIB) stock jumped 8% on late-afternoon trading on Tuesday on rumors that the company could be bought out by either Allergan (AGN) or Merck (MRK), both large-cap pharmaceutical companies.
AGN: 252.53 (+1.78), BIIB: 321.34 (-8.77), MRK: 57.65 (-0.68), IONS: 37.73 (-0.01)
Global Pain Management Therapeutics Market - Patent Expiries of Blockbuster Drugs to Intensify Challenges for Branded Drugs, States TMR; Industry Analysis, Size, Share, Growth, Trends, Forecast up to 2023
PR Newswire Europe - Tue Aug 02, 8:31AM CDT
ALBANY, New York, August 2, 2016 /PRNewswire/ --
PFE: 35.29 (-1.10), MRK: 57.65 (-0.68)
Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 57.65 (-0.68), EXPE: 112.56 (-0.99), ABBV: 66.57 (-0.21), XRX: 9.94 (+0.13)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
Rheumatoid Arthritis (RA) Drugs Markets 2016-2026
PR Newswire Europe - Mon Aug 01, 8:01AM CDT
LONDON, August 1, 2016 /PRNewswire/ --
MRK: 57.65 (-0.68)
Nanoco and Merck Sign Agreement to Market Cadmium-free Quantum Dots
BusinessWire - Mon Aug 01, 8:00AM CDT
Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots (CFQD(R) quantum dots) and other nanomaterials, today announced it has signed a worldwide material supply and licensing agreement with Merck, a leading science and technology company. The license allows Merck to immediately start marketing Nanoco's CFQD quantum dots and to ultimately establish its own production facility to meet growing market demand for this innovative, heavy metal-free material.
MRK: 57.65 (-0.68), NANO: 19.70 (-0.23)
Leading Chief Privacy Officer Hilary Wandall Joins TRUSTe as Demand Escalates for Global Privacy and Data Protection Solutions
PR Newswire - Mon Aug 01, 8:00AM CDT
TRUSTe, the leading Data Privacy Management company, announced today that Hilary Wandall, Associate Vice President, Compliance and Chief Privacy Officer at the global pharmaceutical company, Merck & Co. Inc., has joined TRUSTe as General Counsel and Chief Data Governance Officer. In this role, Hilary will use her extensive global privacy knowledge and operational experience to help TRUSTe further expand their market leading privacy technology and service offerings to support rising global compliance requirements and privacy risk management. She will be a member of the TRUSTe Executive Team and also direct strategic legal, regulatory and privacy related initiatives to help TRUSTe scale its internal business operations.
MRK: 57.65 (-0.68)
Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound
PR Newswire Europe - Mon Aug 01, 7:01AM CDT
- Includes scale-up and GMP manufacturing of drugs in late-stage development
MRK: 57.65 (-0.68)
Mylan Launches Generic Propecia® Tablets
PR Newswire - Mon Aug 01, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Finasteride Tablets USP, 1 mg, a generic version of Merck's Propecia®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
MRK: 57.65 (-0.68), MYL: 48.41 (+1.88)
Business Highlights
By The Associated Press - AP - Fri Jul 29, 4:01PM CDT
___
FDX: 160.61 (+1.43), AMZN: 754.64 (-5.94), BUD: 123.65 (-0.98), MRK: 57.65 (-0.68), SNE: 32.35 (-0.15), BP: 33.01 (-0.44), CVX: 100.61 (+1.02), UPS: 108.29 (+0.83)
Merck (MRK) Breaks Through Resistance at $58.64
Comtex SmarTrend(R) - Fri Jul 29, 9:19AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $58.38 today and have reached the first resistance level of $58.64. Investors may be interested in a cross of the next upside pivot targets of $58.86 and $59.34.
MRK: 57.65 (-0.68)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 123.90 (-0.95), MRK: 57.65 (-0.68), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
